Syk Kinase

An SH2 domain-containing non-receptor tyrosine kinase that regulates signal transduction downstream of a variety of receptors including B-CELL ANTIGEN RECEPTORS. It functions in both INNATE IMMUNITY and ADAPTIVE IMMUNITY and also mediates signaling in CELL ADHESION; OSTEOGENESIS; PLATELET ACTIVATION; and vascular development.

Also Known As:

Networked: 537 relevant articles (15 outcomes, 63 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tsokos, George C: 11 articles (01/2021 - 03/2007)
2.	Grossbard, Elliott B: 9 articles (07/2013 - 04/2005)
3.	Masuda, Esteban S: 8 articles (01/2022 - 01/2006)
4.	Tam, Frederick W K: 8 articles (01/2022 - 02/2010)
5.	McAdoo, Stephen P: 7 articles (01/2022 - 10/2012)
6.	Wang, Lei: 7 articles (09/2016 - 08/2003)
7.	Zirlik, Katja: 6 articles (01/2016 - 07/2009)
8.	Weinblatt, Michael E: 6 articles (12/2014 - 11/2008)
9.	Dai, Jia Le: 6 articles (03/2014 - 08/2003)
10.	Pusey, Charles D: 5 articles (01/2022 - 02/2010)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2012 - "The compounds are Syk kinase inhibitors useful in the treatment of allergic and inflammatory diseases and cancer. " 07/27/2010 - "Drug targeting of C35 or Syk kinase might be helpful in treating a subset of patients with HER2-amplified breast cancers." 11/01/2014 - "To study the effect of gene transfection of full length spleen tyrosine kinase (Syk (L)) on the biological behavior of malignant cancer cells. " 06/01/2023 - "Developing SYK kinase inhibitors has gained significant interest for potential therapeutic applications in neurological and cancer-related conditions. " 01/08/2021 - "The spleen tyrosine kinase (SYK) represents a potential therapeutic target in a subset of B-cell neoplasias. "
2.	Inflammation (Inflammations) 01/01/2018 - "Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis." 01/01/2023 - "Microglial inflammation and phagocytosis are thought to be regulated by spleen tyrosine kinase (Syk), which is activated by multiple microglial receptors, including TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), implicated in neurodegeneration. " 01/01/2021 - "Furthermore, EAPP-2 significantly inhibited the expression and phosphorylation of spleen tyrosine kinase (Syk), a common target regulating both eosinophils and neutrophils inflammation. " 09/15/2020 - "Spleen tyrosine kinase (Syk) has been linked to macrophage-related inflammation in AKI. " 10/01/2017 - "The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita."
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/01/2016 - "Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells." 01/01/2016 - "Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia." 12/01/2014 - "Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia." 07/01/2012 - "Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration." 07/01/2009 - "Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia."
4.	Autoimmune Diseases (Autoimmune Disease) 01/01/2023 - "Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases." 03/01/2022 - "Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases." 04/09/2020 - "Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases." 04/01/2009 - "Spleen tyrosine kinase is considered an attractive drug target for the treatment of allergic and antibody mediated autoimmune diseases. " 09/01/2007 - "Syk kinase as a treatment target for therapy in autoimmune diseases."
5.	Retinoblastoma (Glioblastoma, Retinal) 11/01/2014 - "Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma." 11/01/2014 - "Recent studies characterizing the genomic and epigenomic landscape of retinoblastoma identified spleen tyrosine kinase (SYK) as a promising candidate for targeted therapy. " 02/24/2012 - "However, the recent discovery of aberrant expression of the gene encoding spleen tyrosine kinase (SYK) subsequent to widespread methylation abnormalities in retinoblastoma suggests a potential new therapy for the disease. " 07/20/2020 - "Spleen tyrosine kinase expression and its correlation with necrosis and high-risk histopathologic features in retinoblastoma." 01/01/2016 - "This review discusses advances in these areas, with a focus on discovery and development of small molecules for the treatment of retinoblastoma, including novel targeted therapeutics such as inhibitors of the MDMX-p53 interaction (nutlin-3a), histone deacetylase (HDAC) inhibitors, and spleen tyrosine kinase (SYK) inhibitors. "

Related Drugs and Biologics

1.	fostamatinib
2.	Janus Kinases
3.	Integrins
4.	Chemokines
5.	Tyrosine Kinase Inhibitors
6.	Acetic Acid (Vinegar)
7.	2- (2- aminocyclohexylamino)- 4- (m- tolylamino)pyrimidine- 5- carboxamide
8.	pyrimidine
9.	TAK-659
10.	Cytokine Receptors (Cytokine Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Hyperthermic Intraperitoneal Chemotherapy
5.	Electroacupuncture